13-51941081-C-T

Variant summary

Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PM1PM2PP2PP3_StrongPP5_Very_Strong

The NM_000053.4(ATP7B):​c.3556G>A​(p.Gly1186Ser) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.00000558 in 1,614,006 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1186R) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0000055 ( 0 hom. )

Consequence

ATP7B
NM_000053.4 missense, splice_region

Scores

8
7
3
Splicing: ADA: 1.000
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:16

Conservation

PhyloP100: 4.96

Publications

20 publications found
Variant links:
Genes affected
ATP7B (HGNC:870): (ATPase copper transporting beta) This gene is a member of the P-type cation transport ATPase family and encodes a protein with several membrane-spanning domains, an ATPase consensus sequence, a hinge domain, a phosphorylation site, and at least 2 putative copper-binding sites. This protein is a monomer, and functions as a copper-transporting ATPase which exports copper out of the cells, such as the efflux of hepatic copper into the bile. Alternate transcriptional splice variants, encoding different isoforms with distinct cellular localizations, have been characterized. Mutations in this gene have been associated with Wilson disease which is characterized by copper accumulation. [provided by RefSeq, Dec 2019]
ATP7B Gene-Disease associations (from GenCC):
  • Wilson disease
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Genomics England PanelApp, Orphanet, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 17 ACMG points.

PM1
In a hotspot region, there are 7 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 14 uncertain in NM_000053.4
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 198 curated pathogenic missense variants (we use a threshold of 10). The gene has 32 curated benign missense variants. Gene score misZ: -0.88091 (below the threshold of 3.09). Trascript score misZ: 0.82063 (below the threshold of 3.09). GenCC associations: The gene is linked to Wilson disease.
PP3
Splicing predictors support a deleterious effect. Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
Variant 13-51941081-C-T is Pathogenic according to our data. Variant chr13-51941081-C-T is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 188900.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ATP7BNM_000053.4 linkc.3556G>A p.Gly1186Ser missense_variant, splice_region_variant Exon 16 of 21 ENST00000242839.10 NP_000044.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ATP7BENST00000242839.10 linkc.3556G>A p.Gly1186Ser missense_variant, splice_region_variant Exon 16 of 21 1 NM_000053.4 ENSP00000242839.5

Frequencies

GnomAD3 genomes
AF:
0.00000657
AC:
1
AN:
152130
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.0000942
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.00000801
AC:
2
AN:
249580
AF XY:
0.00000739
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000290
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000883
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000547
AC:
8
AN:
1461876
Hom.:
0
Cov.:
30
AF XY:
0.00000688
AC XY:
5
AN XY:
727238
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33480
American (AMR)
AF:
0.0000224
AC:
1
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26134
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39700
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86254
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53416
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.00000450
AC:
5
AN:
1112004
Other (OTH)
AF:
0.0000166
AC:
1
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.525
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00000657
AC:
1
AN:
152130
Hom.:
0
Cov.:
31
AF XY:
0.0000135
AC XY:
1
AN XY:
74316
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41416
American (AMR)
AF:
0.00
AC:
0
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5200
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4812
European-Finnish (FIN)
AF:
0.0000942
AC:
1
AN:
10614
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
314
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68024
Other (OTH)
AF:
0.00
AC:
0
AN:
2088
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.675
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
0.0000259
Hom.:
0
Bravo
AF:
0.00000756

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:16
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Wilson disease Pathogenic:14
Jul 24, 2014
Counsyl
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.

Dec 22, 2023
Fulgent Genetics, Fulgent Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Aug 10, 2021
Genome-Nilou Lab
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Aug 27, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1186 of the ATP7B protein (p.Gly1186Ser). RNA analysis indicates that this missense change induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs786204547, gnomAD 0.003%). This missense change has been observed in individual(s) with Wilson's disease (PMID: 18371106, 20491539, 24010089; internal data). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as p.G1187S. ClinVar contains an entry for this variant (Variation ID: 188900). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this missense change results in skipping of exon 16, but is expected to preserve the integrity of the reading-frame (PMID: 20491539). For these reasons, this variant has been classified as Pathogenic.

Sep 04, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The ATP7B c.3556G>A; p.Gly1186Ser variant (rs786204547) is reported in the medical literature in several individuals with a clinical diagnosis of Wilson disease (Couchonnal 2021, Lepori 2012, Park 2007, Tatsumi 2010, Zhang 2022) and has been reported in Wilson disease patients with an additional pathogenic variant (Kim 2013, Okada 2010, Yamaguchi 1998). This variant is also reported in ClinVar (Variation ID: 188900) and is only observed on two alleles in the Genome Aggregation Database (v2.1.1), indicating it is not a common polymorphism. Computational analyses predict that this variant is deleterious (REVEL: 0.868). Additionally, this variant is located at the last nucleotide of exon 16 and computational splicing analyses (Alamut Visual Plus v.1.5.1) predict that this variant may impact splicing by weakening the nearby canonical donor splice site. Functional analysis of patient RNA shows skipping of exon 16 (Okada 2010). Based on available information, this variant is considered to be pathogenic. References: Couchonnal E et al. ATP7B variant spectrum in a French pediatric Wilson disease cohort. Eur J Med Genet. 2021 Oct;64(10):104305. PMID: 34400371. Kim JW et al. Genetically confirmed Wilson disease in a 9-month old boy with elevations of aminotransferases. World J Hepatol. 2013 Mar 27;5(3):156-9. PMID: 23556051. Lepori MB et al. Mutation analysis of the ATP7B gene in a new group of Wilson's disease patients: contribution to diagnosis. Mol Cell Probes. 2012 Aug;26(4):147-50. PMID: 22484412. Okada T et al. High prevalence of fulminant hepatic failure among patients with mutant alleles for truncation of ATP7B in Wilson's disease. Scand J Gastroenterol. 2010 Oct;45(10):1232-7. PMID: 20491539. Park S et al. Identification of novel ATP7B gene mutations and their functional roles in Korean patients with Wilson disease. Hum Mutat. 2007 Nov;28(11):1108-13. PMID: 17587212. Tatsumi Y et al. Current state of Wilson disease patients in central Japan. Intern Med. 2010;49(9):809-15. PMID: 20453399. Yamaguchi A et al. Mutations of ATP7B gene in Wilson disease in Japan: identification of nine mutations and lack of clear founder effect in a Japanese population. Hum Mutat. 1998;Suppl 1:S320-2. PMID: 9452121. Zhang S, Yang W, Li X, Pei P, Dong T, Yang Y, Zhang J. Clinical and genetic characterization of a large cohort of patients with Wilson's disease in China. Transl Neurodegener. 2022 Feb 28;11(1):13. PMID: 35220961.

Aug 01, 2023
3billion
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.001%). Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.87; 3Cnet: 0.78). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000188900 /PMID: 9452121).Different missense changes at the same codon (p.Gly1186Arg, p.Gly1186Cys, p.Gly1186Val) have been reported to be associated with ATP7B related disorder (PMID: 24094725, 32911910, 9311736). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline.

Jun 11, 2020
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Gly1186Ser (c.3556G>A; also preported as p.G1187S in the literature) variant in ATP7B has been reported in over 6 individuals with Wilson disease, 6 of whom were compound heterozygous for a second ATP7B variant (Okada 2010, Seo 2012, Shimizu 1999, Tatsumi 2010, Vrabelova 2005, Yamaguchi 1998). This variant has been reported in ClinVar (ID 188900) and has also been identified in 0.002% (1/34528) of Latino and 0.0008% (1/113288) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). This variant is located in the last base of exon 16 of the ATP7B gene, which is part of the splice consensus sequence. This variant is predicted to result in altered splicing. Furthermore, RT-PCR performed on RNA derived from liver tissue from an affected individual indicated that this variant results in skipping of exon 16. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Wilson disease. ACMG/AMP criteria applied: PM3_Strong, PM2, PVS1_Moderate, PP3, PP4.

Dec 18, 2023
All of Us Research Program, National Institutes of Health
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant replaces glycine with serine at codon 1186 of the ATP7B protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies in yeast suggest that this variant does not disrupt copper transport activity, however, there could be a trafficking defect (PMID: 18203200). In addition, this variant alters the conserved, last c.G nucleotide of exon 16 and has been shown to cause in-frame skipping of exon 16 of the ATP7B gene (PMID: 20491539). ATP7B exon 16 (a.a. 1138-1186) encodes a part of functionally important nucleotide-binding (N) domain (a.a. 1032 - 1196) and contains multiple disease-causing missense variants, such as p.Ile1148Thr, p.Gly1149Ala, p.Arg1151Cys, p.Glu1173Lys and p.Thr1178Ala (ClinVar - ATP7B). This suggests that in-frame skipping of exon 16 due to this c.3556G>A variant is likely to disrupt ATP7B gene function. This variant has been reported in individuals affected with Wilson disease (PMID: 10453196, 10790207, 15967699, 17587212, 21645214, 22484412, 22940187, 29930488, 34400371), including seven individuals in the compound heterozygous state with a second pathogenic ATP7B variant in trans (PMID: 9452121, 20491539, 23556051, 25130000, 34866098). This variant has been identified in 2/249580 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic.

Feb 26, 2024
Baylor Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Sep 29, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: ATP7B c.3556G>A (p.Gly1186Ser) results in a non-conservative amino acid change located in the P-type ATPase, haloacid dehalogenase domain (IPR044492) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. Several computational tools predict a significant impact on normal splicing: Two predict the variant abolishes a canonical 5' splicing donor site, and two predict the variant creates a cryptic 3' acceptor site. This predicted impact on mRNA splicing was confirmed via cDNA sequencing of total RNA from patient liver samples, which showed that the variant causes skipping of exon 16 (Okada_2010). The variant allele was found at a frequency of 8e-06 in 249580 control chromosomes (gnomAD). c.3556G>A has been reported in the literature as a biallelic genotype in multiple individuals affected with Wilson Disease (e.g. Yamaguchi_1998, Okada_2010, Kim_2013, Katano_2014). These data indicate that the variant is very likely to be associated with disease. A seperate publication using a yeast complementation assay found that the variant had normal copper transport activity when expressed in a copper transport deficient yeast strain. However, the authors warned that other aspects of normal gene function (e.g. trafficking) may be altered, allowing for no convincing conclusions about the variants effect on protein function (Hsi_2008). Five ClinVar submitters have assessed the variant since 2014: two classify the variant as likely pathogenic, and three as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.

Neuberg Centre For Genomic Medicine, NCGM
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The missense c.3556G>A (p.Gly1186Ser) variant in ATP7B gene has been observed in individual(s) with Wilson's disease (Gojová, L et al.,2008). RNA analysis indicates that this missense change induces altered splicing and likely results in a shortened protein product. Studies have shown that this missense change results in skipping of exon 16, but is expected to preserve the integrity of the readingframe (Okada, Toshihide et al., 2010). This variant is reported with the allele frequency 0.0008% in the gnomAD and novel in 1000 genome database. It has been submitted to ClinVar with varying interpretations: Pathogenic/ Likely Pathogenic. The amino acid Gly at position 1186 is changed to a Ser changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid change p.Gly1186Ser in ATP7B is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Likely Pathogenic. In the absence of second reportable variant , the molecular diagnosis is not confirmed

Mar 17, 2021
Natera, Inc.
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

Jan 30, 2024
Illumina Laboratory Services, Illumina
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The ATP7B c.3556G>A, p.(Gly1186Ser) missense variant has been identified in a homozygous or compound heterozygous state in individuals with Wilson disease (PMID: 9452121; 23556051; 25130000). This variant has also been reported in affected individuals with phase unknown (PMID: 15967699; 20453399; 29930488). This variant is not observed at a significant frequency in version 2.1.1 or version 4.0.0 of the Genome Aggregation Database. This variant occurs at the intron/exon boundary of exon 16 and is predicted to result in a splicing defect. This has been confirmed experimentally with the variant demonstrated to result in exon skipping of exon 16 in an individual with Wilson disease (PMID: 20491539). The c.3556G>A variant has been classified as pathogenic by multiple submitters in ClinVar. The variant is identified in a homozygous state in the proband. Based on the available evidence, the c.3556G>A, p.(Gly1186Ser) variant is classified as pathogenic for Wilson disease.

Jun 03, 2025
Revvity Omics, Revvity
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Inborn genetic diseases Pathogenic:1
Apr 11, 2016
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.3556G>A pathogenic mutation (also known as p.G1186S), located in coding exon 16 of the ATP7B gene, results from a G to A substitution at nucleotide position 3556. The amino acid change results in glycine to serine at codon 1186, an amino acid with similar properties. This alteration has been identified in the compound heterozygous state in several patients with Wilson disease (Yamaguchi A et al. Hum Mutat 1998;Suppl1:S320-2; Okada T et al. Scand J Gastroenterol 2010; 45 (10) :1232-7; Kim JW et al. World J Hepatol 2013; 5(3):156-9). The c.3556G>A pathogenic mutation changes the last base pair of coding exon 16, which makes it likely to have some effect on normal mRNA splicing. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice donor site. In addition, this mutation has been shown to cause exon 16 skipping as verified by RT-PCR using total RNA extracted from the liver of a patient with Wilson disease (Okada T et al. Scand J Gastroenterol 2010; 45 (10) :1232-7). In our internal cohort, this alteration was detected in trans with a known pathogenic mutation in ATP7B in an individual with Wilson disease. Based on the supporting evidence, c.3556G>A is interpreted as a disease-causing mutation.

not provided Pathogenic:1
Oct 17, 2023
Mayo Clinic Laboratories, Mayo Clinic
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PP3, PP5, PM2_moderate, PM3, PM5

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.13
BayesDel_addAF
Pathogenic
0.41
D
BayesDel_noAF
Pathogenic
0.43
CADD
Pathogenic
32
DANN
Uncertain
0.99
DEOGEN2
Pathogenic
0.93
D;D;.;.;.;.;.
Eigen
Uncertain
0.63
Eigen_PC
Uncertain
0.60
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.94
D;D;D;D;D;D;D
M_CAP
Pathogenic
0.75
D
MetaRNN
Pathogenic
0.99
D;D;D;D;D;D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Uncertain
2.0
M;.;.;.;.;.;.
PhyloP100
5.0
PrimateAI
Uncertain
0.60
T
PROVEAN
Uncertain
-3.5
D;D;D;D;D;.;D
REVEL
Pathogenic
0.87
Sift
Benign
0.045
D;T;D;D;D;.;T
Sift4G
Benign
0.069
T;T;T;T;D;T;T
Vest4
0.77
ClinPred
0.97
D
GERP RS
5.0
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.0
Varity_R
0.54
gMVP
0.92
Mutation Taster
=0/100
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
1.0
Splicevardb
3.0
SpliceAI score (max)
0.78
Details are displayed if max score is > 0.2
DS_DL_spliceai
0.78
Position offset: 0

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs786204547; hg19: chr13-52515217; COSMIC: COSV54439123; COSMIC: COSV54439123; API